Comment
doi: 10.1016/j.ejca.2023.112979.
Epub 2023 Jul 31.
Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design
Affiliations
- PMID: 37532597
- DOI: 10.1016/j.ejca.2023.112979
Item in Clipboard
Comment
Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design
Eur J Cancer.
2023 Sep.
No abstract available
Conflict of interest statement
Declaration of Competing Interest None.
Comment in
-
Response to letter entitled: Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.Eur J Cancer. 2023 Sep;191:112980. doi: 10.1016/j.ejca.2023.112980. Epub 2023 Aug 11. Eur J Cancer. 2023. PMID: 37574396 No abstract available.
Comment on
-
Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.Eur J Cancer. 2023 Jul;187:124-133. doi: 10.1016/j.ejca.2023.03.039. Epub 2023 Apr 7. Eur J Cancer. 2023. PMID: 37149961 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources